Improved Clinical Outcomes in HCT: A Donor and Patient Perspective*
Wednesday, January 11, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124690
Developed in Conjunction with the National Marrow Donor Program
Director/Moderator: John Miller, MD, PhD
Speaker: Navneet S. Majhail, MD, MS
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate
Objectives:
- Explain the current state of donor recruitment to the NMDP registry and how this has affected match rates for donors and their recipients.
- Describe how survival after HCT has changed over time and what donor and patient factors may have led to these changes.
- Review how more efficient systems and processes may affect transplant outcomes now and in the future.
Event Description: Since the first successful allogeneic hematopoietic cell (HC) transplants occurred using unrelated donors in the early 1970's, donor registries have grown to over 15 million HLA typed potential donors and over 12,000 unrelated donor transplants occur annually worldwide. This session will address the question of clinical outcomes of HCT. We continue to grow the number of donors on the NMDP registry and we are performing an ever increasing number of transplants for patients in need, but have we improved donor match rates and patient survival rates over the past several decades? This session will address the donor and patient related factors that impact clinical outcomes for the transplant patient and how donor registries and transplant physicians might continue to improve outcomes of transplantation in years to come.
*Cellular Therapy-focused Audioconference.
Purchase the Presentation
Knowledge Discovery Through Patient Safety Event Analysis: Using Hemovigilance Data to Improve Performance
FREE SESSION - This program has been postponed due to a family emergency. New date will be announced in early February, 2012
Wednesday, January 18, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124724
Director/Moderator: Barbee Whitaker, PhD
Speaker: Barbara Rabin, MHA, MT(ASCP)SC, BB
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors
Teaching Level: Intermediate
Objectives:
- Define classification systems for various types and causes of medical errors.
- Determine why the study of near miss events is important and how it is a part of hemovigilance.
- Review multiple methods of analyzing patient safety events, both singular and in aggregate.
- Walk through the causal tree-building method of root cause analysis.
- Discuss the association between a learning environment/just culture and patient safety.
Event Description: This program will discuss how adverse event reporting and investigation are critical components of effective hemovigilance. Classification, patient safety, and root cause analysis will be discussed. The information will be presented as a lecture including examples.
One free registration per site is offered for this program.
Register Now
ARDP (American Rare Donor Program): Overview and Case Studies
Wednesday, February 1, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124692
Director/Moderator: Kristina Williams, MT(ASCP)SBB, CQIA, CQA(ASQ)
Speaker: Cynthia Flickinger, MT(ASCP)SBB
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors
Teaching Level: Intermediate
Objectives:
- Describe how the different elements of the ARDP come together to comprise a fully-functioning program.
- Review program metrics regarding program request rates and fill rates.
- Review and discuss ARDP-related case studies/scenarios.
Event Description: On November 1, 1998, the American Rare Donor Program (ARDP) was formed after merging the ARC Rare Donor Registry and the AABB Rare Donor File. The associated computer database is maintained by the American Red Cross (ARC) and is accessible by the ARDP staff at the Philadelphia, PA site. Although the ARDP specifically deals with rare donors and rare patient requests, the rarest blood product is truly that product that is unavailable when needed. It is through the dedicated efforts of donors, technologists, volunteers, office staff, doctors, nurses, international contacts, couriers, and even airport customs staff, that the blood supply is maintained and the ARDP can be effective. Some of the high-level case studies to be presented in this program will illustrate some of these very interesting and complex scenarios how the ARDP process is executed.
Register Now
Leadership Management Audioconference for Individuals: Medical Event Reporting and Error Management
Tuesday, February 7, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 1200
Director/Moderator: Dina Hannah, MBA/HCM, BS, MT(ASCP)H, SBB, CIPP
Speaker: Karen Nielsen, MBA, MT(ASCP)SBB
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors
Teaching Level: Intermediate
Objectives:
- Discuss how a Medical Event Reporting System (MERS) fits into process control for an organization.
- Identify characteristics of an effective error management program.
- Improve event investigation and action processes.
- Apply error management concepts to various case studies.
Event Description: It is estimated that between 44,000 and 98,000 deaths occur annually in the U.S. due to medical mistakes. This presentation will use a case study approach to examine how systems and processes in the blood bank and laboratory can affect patient outcomes. This presentation focuses on helping participants identify "near misses" and examine process changes that can reduce or eliminate the opportunity for error.
Register Now
Industry and Academic Collaborations: Opportunities and Challenges*
Wednesday, February 8, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124693
Director/Moderator: Linda Kelley, PhD
Speaker: Robert Deans, PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors
Teaching Level: Intermediate
Objectives:
- Discover advantages to academia and industry collaborations.
- Develop tools to establish win/win collaborations.
- Review how to avoid pitfalls and protect the interest of all parties.
- Determine how to leverage your success to enhance your growth opportunities.
Event Description: How does an academic PI attract sponsors after developing a CT product or device? How does Industry engage academic sites to participate when they develop a CT product or device? What meetings are available that foster collaborations between academic/industry? — This program will review the process to develop, evaluate and implement collaboration between academia and industry. The speakers will provide examples that illustrate when academic/industry interests favor a collaboration, illustrating both successful and challenging collaborations. • The presentation will describe types of agreements/contracts that should be in place for collaborations and the critical points that are needed in these documents.
*Cellular Therapy-focused Audioconference.
Register Now
Preventive Actions for Reactions from First Time Donors and High School Donors
Wednesday, February 15, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124694
Director/Moderator: Meghan Delaney, DO, MPH
Speakers: Peter Tomasulo, MD; Nancy Dunbar, MD
Intended Audience: Physicians, Nurses, Managers/Supervisors
Teaching Level: Intermediate
Objectives:
- Describe reactions common to all blood donors and identify those specific types for which young donors are at increased risk.
- List specific interventions blood collection facilities have implemented to reduce the risk of faint and pre-faint reactions in young donors and interpret the impact of these interventions reported in recently published studies.
- Describe the risk factors for vasovagal reaction during the various phases of the whole blood donation process.
- Evaluate educational interventions to improve donor outcomes.
Event Description: During this audioconference, there will be a brief overview of the incidence of adverse events in the setting of blood donation and the donor criteria established to minimize risk. The speakers will review the evidence demonstrating an increased risk of vasovagal reactions in young donors and the impact of interventions recently implemented by blood collection facilities to reduce reaction rates in this high risk group. The presentation will broaden to review the physiology of the whole blood donation process. Iron deficiency, needle related injuries and other risks to donors will be considered. Education to empower the donor to reduce donation risk through preventing acute and delayed adverse events will be discussed.
Register Now
Best Practices for Audits, Internal and External - NEW
Wednesday, February 29, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124695
Director/Moderator: Gail Moskowitz, MD
Speaker: Lisa Walters, PhD, MBA, MT(ASCP)SBB, QSA(A2LA); JoAnne MacDonald
Teaching Level: Intermediate
Objectives:
- Identify the critical aspects of policies driving internal and external assessments.
- Determine how to conduct both internal and external assessments.
- Review how observations should lead into improvement.
Event Description: This audioconference is designed to address issues related to both internal and external assessments, from establishing an assessment program through follow-up of assessment findings. The development of internal and external assessment programs, including prioritization of scheduling, items to be included, the assessor policy, and the strategy to manage external assessments will be discussed. The components of pre-assessment preparation, including scope, authoritative documents, assessor selection, and desk audits will be reviewed. In addition, aspects of the assessments themselves, including sampling, interviewing techniques, conclusions, and writing finding/observations will be presented. Finally, post-assessment management and the use of the assessment findings will be discussed for both internal and external assessments. How to identify differences in the extent of actions required in response to the findings will be reviewed, as will the differences between corrective action and preventative action and when each is indicated. By the conclusion of the audioconference, sites should have the tools necessary to conduct internal and external assessments that are both effective and valuable.
Register Now
The Role of Clinical Trial INDs in Supporting the Biologics License Application*
Wednesday, March 7, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124696
Director/Moderator: Fran Rabe, MS, CQM(ASQ)
Speaker: Scott Burger, MD
Intended Audience: Physicians, Scientists, Managers/Supervisors
Teaching Level: Advanced
Objectives:
- Describe the role of clinical trial INDs in supporting future BLA submissions.
- Discuss the importance of, and restrictions associated with, product labeling claims.
- Review the significance of IND primary and secondary end points as they relate to safety, purity, identity, and potency labeling claims.
Event Description: An investigational new drug (IND) application is not only required prior to clinical trial, it is fundamental to support a successful future biologic license application (BLA). The IND application, including its clinical and manufacturing elements, must contribute to the product development plan. While the IND must include the elements specified in 21 CFR 312, selection of effective clinical study parameters will enable compliance with BLA requirements to demonstrate product safety, purity, identity and potency, while allowing the desired product claims. This program will illustrate the role of and significance of clinical trials supporting future BLA submissions.
*Cellular Therapy-focused Audioconference.
Register Now
The Future of Bone Marrow vs. HPC*
Wednesday, March 14, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124697
Director/Moderator: Meghan Delaney, DO, MPH
Speaker: Dennis Confer, MD
Intended Audience: Physicians, Technologists, Nurses
Teaching Level: Intermediate
Objectives:
- Describe different methods for hematopoetic stem cell collection.
- Review the side effects to the hematopoetic stem cell donor and their relation to the type of donation.
- Describe how the hematopoetic stem cell source (bone marrow or peripheral blood stem cells) may affect transplant patient outcomes.
Event Description: How are hematopoetic stem cells from a bone marrow collection different from those collected using apheresis from peripheral blood? Does the method of stem cell collection affect patient outcomes? Details specific to both types of collections, as well as outcomes that may be related to the stem cell source, will be discussed in this program.
*Cellular Therapy-focused Audioconference.
Register Now
A Very Unique Test to Discover Etiology of TRALI
Wednesday, March 28, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124698
Director/Moderator: Monica LaSarre, MT(ASCP)SBB
Speakers: Chris Silliman, MD, PhD; Tuan Le, MD
Intended Audience: Physicians, Scientists, Technologists, Managers/Supervisors
Teaching Level: Intermediate
Objectives:
- Review the definition of TRALI, including accepted etiologies.
- Discover models of TRALI etiology investigations used by laboratories/donor centers in the U.S.
- Become familiar with the role of the neutrophil priming assay in illuminating the etiology of TRALI in specific investigations.
Event Description: TRALI continues to be an important topic in transfusion medicine. Investigating whether TRALI occurred and what the donor and/or patient etiology of TRALI is continues to be poorly defined and standardized amongst laboratories and donor centers. This program will review an across-the-U.S. look at how TRALI is being investigated. Also, a specific assay that may be underutilized in TRALI investigations will be discussed.
Register Now
Challenges of Real-Time CT Product Evaluation*
Wednesday, April 4, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124699
Director/Moderator: Elina Linetsky, MT, PhD
Speakers: Elina Linetsky, MT, PhD; Janice Davis-Sproul, MAS, MT (ASCP) SBB; Sharon Tindle, MS, CQA (ASQ)
Intended Audience: Technologists, Managers/Supervisors
Teaching Level: Intermediate to Advanced
Objectives:
- Review how different types of CT facilities handle problems encountered during product testing.
- Discuss various approaches to handling release of products in low staffing situations such as small laboratories or nights and weekend shifts.
- Compare strategies for exceptional release of CT products that fail to meet release criteria.
- Compare strategies for release of novel cell therapy products.
Event Description: Cell therapy (CT) products must be tested and then released for distribution to make certain that products that do not meet specified requirements are either not distributed or are handled appropriately to ensure the safety of patients. A challenge is testing and release of novel cell therapy products. These seemingly simple issues actually present many significant challenges for CT Laboratories. How many replicates should be performed? When is repeat testing permitted and how is it handled? How do you release a product from overseas in the middle of the night? Who needs to approve and be notified of exceptional release of products that do not pass all testing and how is that handled? What type of testing is applicable to novel cell therapy products? These challenges and how they are met will vary depending on the size of the laboratory and the complexity of the manufacturing process. A panel of speakers from facilities of different sizes and organizational structures will discuss how they would handle different testing and release scenarios.
*Cellular Therapy-focused Audioconference.
Register Now
What is a Patient Safety Organization and How Can AABB's Patient and Donor Safety Center Help with Hemovigilance?
FREE SESSION
Wednesday, April 11, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124725
Director/Moderator: Barbee Whitaker, PhD
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors
Teaching Level: Intermediate
Objectives:
- Review AABB's Patient and Donor Safety Center, a listed PSO, and its role in hemovigilance.
- Discuss analysis of hemovigilance data within NHSN.
- Discuss additional analyses that can be obtained through AABB's Patient and Donor Safety Center.
Event Description: This program will explain how AABB's Patient and Donor Safety Center will work with hospital members to better understand adverse reactions and incidents occurring in the transfusion process.
One free registration per site is offered for this program.
Register Now
Leadership Management Audioconference for Individuals: Creative Interactive Training Tools
Tuesday, April 17, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 1201
Director/Moderator: Colleen Aronson, MT(ASCP)SBB
Speakers: Angela Turner; Elizabeth Werner
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, Perfusionists
Teaching Level: Basic to Intermediate
Objectives:
- Compare adult learning concepts to create learning tools that will reduce problems, increase compliance, and improve communication between departments.
- Discuss how to create interactive learning tools through the use of game models.
- Show how interactive learning tools can be used by collection staff alone, in small groups, and all staff meetings, reaching as many as 600 in a cost effective manner.
- Discuss creative educational tools designed to improve interdepartmental problem solving.
Event Description: Today's blood centers face the challenge of designing educational tools that create enthusiasm to reduce problems, ensure compliance, and ensure a safe blood supply. In addition, there is a need to improve communication between departments regarding procedures at blood drives. This educational session will present creative cost effective interactive tools, which cross generational and functional lines and create an environment conducive to learning, contributing to a significant impact in problem reduction. The curriculum designs, modeled after game shows, provide flexibility during non peak donor times and create fun competition amongst staff as well as enthusiasm and excitement.
Register Now
Method Comparability Between Different Platforms: Gel vs. Tube
Wednesday, April 18, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124700
Director/Moderator: Shelvi McFadden, MLS(ASCP)
Speakers: Shelvi McFadden, MLS(ASCP); Roger Bertholf PhD, DABCC, FACB
Intended Audience: Physicians, Scientists, Technologists, Managers/Supervisors
Teaching Level: Intermediate
Objectives:
- Determine why we need to perform method comparability.
- Review what is involved in performing method comparability.
- Discuss at what frequency should we do method comparison testing.
- Review an example of method comparability protocol in Transfusion Service.
Event Description: Method comparability (the importance of method comparison testing) compares the primary test method with other comparative test methods that are in use within a laboratory. For transfusion service facilities, this comparison is performed with quality control testing when different testing platforms are being used. This program will look at the background of method comparison testing and an example protocol for a transfusion service.
Register Now
Autologous Blood Management
Wednesday, April 25, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124701
Director/Moderator: Gail Moskowitz, MD
Speakers: Aryeh Shander, MD, FCCM, FCCP; Jonathan Waters, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, CEOs/CFOs
Teaching Level: Intermediate
Objectives:
- Describe the advantages and disadvantages of autologous blood.
- Assess the development of an autologous blood program.
- Review strategies for gaining acceptance from clinicians and administrators.
- Define strategies to initiate an autologous program.
Event Description: Although not a new topic in blood banking, autologous blood collection and usage can be challenging. This audioconference will present the advantages and disadvantages of autologous blood in comparison to banked blood. How to develop and implement an autologous blood program will be discussed. Ways to encourage participation by both clinicians and administrators will be described, as will expected economic outcomes. By the conclusion of this audioconference, participants should have a framework to use for the establishment of an autologous blood program.
Register Now
SBB Schools Update
Wednesday, May 2, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124702
Director/Moderator: Jayanna Slayten, MS, MT(ASCP)SBB
Speaker: Theresa Pringle, MT(ASCP)SBBcm
Intended Audience: Scientists, Technologists, Managers/Supervisors
Objectives:
- Review application process for an SBB program.
- Discuss what to expect in an SBB program.
- Share the experiences from two different SBB distance programs.
- Provide perspective on time management and learning strategies while in the SBB program.
Event Description: Many in transfusion medicine have a goal of obtaining an SBB certification. There are several options for SBB programs through CAAHEP/AABB, but many blood bankers are choosing receive their education through distance education. This program shares the experiences of two distance SBB students. They will review, from application to SBB success, what one can expect in this type of a training program.
Register Now
Drug Induced Immune Hemolytic Anemia
Wednesday, May 9, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124703
Director/Moderator: Michele Anastasi, MS, MT(ASCP)SBB
Speakers: George Garratty, PhD, FRCPath; Pat Arndt, MS, MT(ASCP)SBB
Intended Audience: Physicians, Technologists, Managers/Supervisors
Teaching Level: Intermediate
Objectives:
- Describe the different mechanisms of DIIHA.
- Identify drugs commonly associated with immune Hemolysis.
- List laboratory tests useful for making the diagnosis of DIIHA.
- Assess the serologic findings associated with DIIHA.
Event Description: Drug-induced immune hemolytic anemia (DIIHA) should be considered whenever any hemolytic anemia is suspected. More than 100 drugs can cause a positive direct antiglobulin test (DAT) and, in some patients, this will be associated with significant hemolysis. This session will review the pathophysiology of DIIHA, laboratory investigations, and examples of case histories.
Register Now
Advances in the Treatment of Older Patients with Acute Leukemia*
Wednesday, May 23, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124705
Director/Moderator: Karen Kuhn Ballen, MD
Speakers: Thomas H. Price, MD; Meir Wetzler, MD; Amir Fathi, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors
Teaching Level: Intermediate
Objectives:
- Review the challenges of treatment for older patients with acute leukemia.
- Assess new treatments and medications for patients with acute leukemia.
- Discuss complexities of transfusion support for patients with acute leukemia.
Event Description: Acute Leukemia is a devastating disease, with a 5 year survival of less than 10% in patients over age 60. During this program, new treatment modalities will be explored in lectures by experts in the field. Transfusion support for these patients will be reviewed.
*Cellular Therapy-focused Audioconference.
Register Now
Leadership Management Audioconference for Individuals: Staff Training and Competency
Tuesday, June 5, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 1202
Director/Moderator: Dina Hannah, MBA/HCM, BS, MT(ASCP)H, SBB, CIPP
Speaker: Karen Nielsen, MBA, MT(ASCP)SBB
Intended Audience: Technologists, Nurses, Managers/Supervisors
Teaching Level: Basic to Intermediate
Objectives:
- Discuss the differences between education, training, and competence.
- Describe the key elements of training programs.
- List the required elements of competency testing.
- Design assessment tools to verify competency.
Event Description: Essential components of a quality system include employee training and competence assessment. Regulatory agencies require documentation of training and competency prior to the individual performing any patient testing, semiannually during the first year, and annually thereafter. This presentation will focus on identifying the elements of competency assessment and provide examples of methods to document competency assessment tools and records.
Register Now
Molecular Testing: Working Hand in Hand with Serology
Wednesday, June 13, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124707
Director/Moderator: Kristina Williams, MT(ASCP)SBB, CQIA, CQA(ASQ)
Speaker: Trina Horn, MS
Intended Audience: Physicians, Scientists, Technologists, Managers/Supervisors
Teaching Level: Intermediate to Advanced
Objectives:
- Provide an overview of molecular testing.
- Discuss current manual methods and automated platforms used in the molecular lab.
- Highlight specific cases where molecular testing was used to aid difficult serology.
Event Description: This program will give a basic overview of molecular genetics as it applies to blood group antigens. The various types of tests and methodologies currently used in the molecular laboratory and when the different methods are used will be discussed. Lastly, the importance of the relationship between serology and molecular methods will be emphasized through several interesting case studies.
Register Now
Collection of HPC Products from High Risk Patient and Donors*
Wednesday, June 20, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124708
Director/Moderator: Michele Sugrue, MS, MT(ASCP)SBB
Speakers: Joseph Schwartz, MD; Paul V. O'Donnell, MD, PhD, FACP; Corina Gonzalez
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors
Teaching Level: Basic to Intermediate
Objectives:
- Review the standard approach for evaluation and risk assessment for patients and donors undergoing marrow harvest for HPC(M) collection along with the safety and outcome data for marrow harvest.
- Review the standard approach for evaluation and risk assessment for patients and donors undergoing mobilization and collection of HPC(A) by apheresis along with the safety and outcome data for collection.
- Discuss the evaluation, risk stratification and management approaches for high risk patients and donors with significant medical co-morbidities that impact the safety of marrow harvest under anesthesia or mobilization and apheresis collection of HPC(A).
- Discuss the ethical standards and advocacy practices for HPC donor recruitment, evaluation, management and research participation along with situations that could compromise optimal donor care.
Event Description: Hematopoietic progenitor cells (HPCs) harvested from the marrow [HPC(M)] or mobilized and collected from the blood by apheresis [HPC(A)] are used for autologous and most allogeneic hematopoietic stem cell transplants. Autologous HPCs are also used for regenerative medicine and other cell-based therapies. Precollection assessments and optimal management require an understanding of baseline risks, potential toxicities and additional effects of medical co-morbidities on anesthesia and marrow harvest [for HPC(M)] or on mobilizing agents and apheresis [for HPC(A)]. Donor autonomy and advocacy, including psychosocial effects of recruitment, consent, management and research participation, must also be ensured. In this audioconference, case studies, safety and outcome data and ethical standards for donors and patients undergoing HPC collection will be reviewed as a framework for discussions of higher risk individuals with significant medical co-morbidities and/or ethical considerations. Strategies for risk stratification, medical management and donor advocacy will be discussed.
*Cellular Therapy-focused Audioconference.
Register Now
Neonatal Testing and Transfusion Practices
Wednesday, June 27, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124709
Director/Moderator: Michele Anastasi, MS, MT(ASCP)SBB
Speakers: Meghan Delaney, DO, MPH; Cassandra Josephson, MD
Intended Audience: Physicians, Technologists, Nurses
Teaching Level: Intermediate
Objectives:
- Discuss the pre-transfusion compatibility testing for neonatal patients.
- Cite various blood bank approaches for blood products for neonatal patients.
- Describe current practices about transfusion thresholds in neonatal patients.
- Assess how transfusion related acute gut injury and ABO incompatible plasma affects neonatal patients.
Event Description: Neonatal patients require specialized testing and blood products for transfusion. In addition, there are specific regulations that guide blood bank practice in this patient population. In this audioconference, the transfusion of neonatal patients will be discussed from the perspective of the blood bank and from the practicing clinician. Additionally, adverse events due to transfusion will be reviewed, including transfusion-related acute gut injury (TRAGI) and incompatible plasma.
Register Now
When Professions Meet: Bridging the Gap Between Laboratory and Nursing
Wednesday, July 11, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124710
Director/Moderator: Dina Hannah, MBA/HCM, BS, MT(ASCP)H, SBB, CIPP
Speaker: Lucinda (Cindy) Manning, BA, MT(ASCP), RN
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors
Teaching Level: Basic to Intermediate
Objectives:
- Identify the different models for learning by the laboratory and nursing professions.
- Identify barriers to communication between the two professions.
- Explore strategies to build strong positive relationships between laboratory and nursing staff.
Event Description: This session will compare the differences in learning within the laboratory and nursing professions. Personal examples illustrating the struggles each profession has in understanding each other will be discussed. The speaker will explore practical ways to bridge the gaps in understanding between the two professions. There will be time during the presentation to discuss the issues you may be facing within your own organizations in regards to the laboratory/nursing interactions and ways to enhance those relationships. The audience will be given an opportunity to share problems as well as best practices and successes in bridging the gap between these two professions.
Register Now
Benefits of the Donor Hemovigilance System for Blood Centers
FREE SESSION
Wednesday, July 18, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124726
Director/Moderator: Barbee Whitaker, PhD
Speaker: Kevin Land
Intended Audience: Physicians, Managers/Supervisors, Perfusionists
Teaching Level: Intermediate
Objectives:
- Explain how to register for and use Donor HART, the Donor Hemovigilance System
- List the benefits of using this system for your blood center.
- Describe the value of donor hemovigilance on a national level.
Event Description: This program will provide an introduction to the Donor Hemovigilance website and a demonstration of data entry and report generation in the Donor Hemovigilance System. The speaker will also discuss benefits of participation and use of the system. Ample time for questions will be available. One free registration per site is offered for this program
One free registration per site is offered for this program.
Register Now
Case Study Approach to Root Cause Analysis: Transfusion Service Perspective
Wednesday, July 25, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124711
Director/Moderator: Jayanna Slayten, MS, MT(ASCP)SBB
Speakers: Beth Hughes, MT(ASCP); Kristine Beltz,; Kim Coors, MT(ASCP)
Intended Audience: Physicians, Technologists, Managers/Supervisors
Teaching Level: Basic to Intermediate
Objectives:
- Review the root cause analysis tools.
- Apply these root cause analysis tools in case studies from the transfusion service.
- Discuss opportunities for process improvement with the use of root cause analysis tools in the transfusion service.
Event Description: Root cause analysis tools, when applied appropriately and effectively, allow a transfusion service to respond to errors. In an effort to present how to efficiently use these tools, this program will present a group of case studies applying root cause analysis for error management and corrective and preventative action strategies in the transfusion service.
Register Now
Serological Case Studies: Unexpected/Odd Outcomes
Wednesday, August 1, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124712
Director/Moderator: Monica LaSarre, MT(ASCP)SBB
Speakers: Agnes Lee-Stroka, MT(ASCP)SBB; Karen Byrne
Intended Audience: Technologists, Managers/Supervisors
Teaching Level: Intermediate to Advanced
Objectives:
- Describe immunohematology case studies with an odd/unexpected outcome.
- Review antigens/antibodies discussed as part of the case study approach.
- Review immunohematology testing techniques useful in resolving complex investigations.
Event Description: The age-old addage of, "There's more than meets the eye!" applies as much to the immunohematologist as to anyone else. In a case study approach, this session will cover immunohematology investigations where the initial RBC antibody identification or clinical scenario was vastly different from the final conclusion at the end of the investigation. The cases presented here will prove that, in immunohematology, it is a benefit to keep an open mind until the very end of an investigation, since there may be a surprising or odd outcome at the end!
Register Now
Leadership Management Audioconference for Individuals: Understanding the Cost of Quality: How to Talk to Executive Management About It
Tuesday, August 7, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 1203
Director/Moderator: Shelvi McFadden, MLS(ASCP)
Speaker: Galen Kline, BS, LSSBB
Intended Audience: Technologists, Managers/Supervisors
Teaching Level: Basic to Intermediate
Objectives:
- Identify what the cost of quality is.
- Explain quality metrics in the language of money.
- Develop a cost of quality business case presentation for executive management demonstrating how quality initiatives through process improvement benefit the organization financially.
Event Description: The "cost of quality" isn't the price of creating a quality service or product. It's the cost of NOT creating a quality service or product. During this interactive session, attendees will learn the four categories of quality costs and how to apply these to an organization-specific process improvement opportunity. Using a case study, speakers will demonstrate how to develop a business case for process improvements to present to executive management by adding the language of money and financial performance to the language of statistics and quality metrics.
Register Now
Status of Bloods Banks in US Mergers and Acquisitions
Wednesday, August 8, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124713
Director/Moderator: Meghan Delaney, DO, MPH
Intended Audience: Physicians, Managers/Supervisors, CEOs/CFOs
Teaching Level: Intermediate
Objectives:
- Review the concept of mergers as a business strategy.
- Determine how mergers may be beneficial and at the same time challenging to a blood center.
- Review the healthcare economic issues that lead to mergers.
Event Description: Blood centers have recently been merging with one another to create larger blood centers. Why is this happening? What are the challenges in the healthcare economy that support the increased rate of mergers? What are the benefits achieved through merging? These issues will be discussed by experts in the field.
Register Now
Changing to a No-Blame Culture for Error Management
Wednesday, August 22, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124714
Director/Moderator: Colleen Aronson, MT(ASCP)SBB
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, Perfusionists
Teaching Level: Basic to Intermediate
Objectives:
- Describe how to have an error management system that is effective without being punitive.
- Analyze trends that may be related to procedures and practices rather than individuals.
- Discuss approaches for corrective action that are affective but not punitive.
Event Description: Organizations face difficulties when attempting to move to a collaborative, supportive error management system. During this session we will discuss the challenges inherent in the process, methods that facilitate a widespread problem-solving mentality among staff, and skills that aid supervisory staff in this journey.
Register Now
Sickle Cell Disease: Overview and Transfusion Support
Wednesday, August 29, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124715
Director/Moderator: Shelvi McFadden, MLS(ASCP)
Speaker: Jeanne Hendrickson, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors
Teaching Level: Intermediate
Objectives:
- Define sickle cell disease and determine what population is affected.
- Assess the indications for transfusion of sickle cell patients.
- Review potential adverse outcomes of transfusion in sickle cell patients (e.g. RBC alloimmunization and delayed hemolytic transfusion reactions).
Event Description: Sickle cell patients can pose quite a challenge on a transfusion service. Each hospital facility has their own protocol on how to handle these patients and that may vary between different hospitals within the same regional area. This program will look at the most effective way to manage sickle cells patients with testing and transfusion support.
Register Now
How Much Does this Cost? Developing Procedure Charges in CT*
Wednesday, September 12, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124716
Director/Moderator: Kevin Bundy, BS, SBB, MT, BB, CLS
Speakers: Kevin Bundy, BS, SBB, MT, BB, CLS; Gary Goldstein
Intended Audience: Technologists, Managers/Supervisors, CEOs/CFOs
Teaching Level: Basic to Intermediate
Objectives:
- Describe the basic elements of workload recording.
- Describe the information needed to calculate the cost per product manufacture.
- Outline the billing process for cell processing charges and highlight billable vs. non-billable services.
- Explore reimbursement scenarios for charges covered by grants, Medicare, or commercial payors.
Event Description: This presentation will describe the basic elements of workload recording and one approach for using the information to calculate the cost associated with manufacturing a cell therapy product. The second half of the presentation will discuss the billing process for cell processing charges, and will explore different reimbursement scenarios.
*Cellular Therapy-focused Audioconference.
Register Now
Computerized Crossmatches
Wednesday, September 19, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124717
Director/Moderator: Michele Anastasi, MS, MT(ASCP)SBB
Speaker: Suzanne Butch, MA, MLS(ASCP)SBB
Intended Audience: Physicians, Technologists, Managers/Supervisors
Teaching Level: Intermediate
Objectives:
- Discuss AABB's requirements for what must be performed prior to blood being transfused.
- Discuss the essential components of a computer system to ensure patient safety when using an electronic crossmatch.
- Design an electronic crossmatch process or standard operating procedure.
- Outline the steps to implement an electronic crossmatch.
Event Description: The crossmatch is known as a way to help ensure compatibility of blood between a donor and its recipient. Crossmatch procedures must therefore be designed in a manner to provide the safest blood as quickly as possible. The advancements of laboratory information systems in transfusion services have lead to the emergence of computer crossmatches. It is now possible for blood banks to develop procedures which work with laboratory information systems to develop an electronic crossmatch that can replace the immediate spin crossmatch. The speaker in this session will take a closer look at the needs of an adequate LIS to accommodate an electronic crossmatch and discuss how it meets the certifying bodies' requirements for transfused blood. With this knowledge, a standard operating procedure can be developed. Finally, the program will focus on the actual steps to take to implement an electronic crossmatch in your laboratory and describe the necessary elements that will be needed to document the validation of your system.
Register Now
Preparing for Your First FDA Inspection
Wednesday, September 26, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124718
Director/Moderator: Colleen Aronson, MT(ASCP)SBB
Speaker: Kenneth Hudson, BS, MT (ASCP)
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors
Teaching Level: Basic
Objectives:
- Review actions to have in place prior to the inspection.
- Discuss best practices during the inspection
- Review things NOT to do during the inspection.
Event Description: When an inspection is expected, it's helpful to know how to get organized and know what to have ready when the inspector walks in the door. This session will review some of the preparation steps and the dos and don'ts of being inspected.
Register Now
ABO-Incompatible Hematopoietic Stem Cell Transplantation (HSCT) Practical Considerations: Patient and Product Testing, Release Criteria, and Transfusion Policies*
Wednesday, November 7, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124720
Director/Moderator: Michele Sugrue, MS, MT(ASCP)SBB
Speakers: Jeffrey Jhang, MD; Anand Padmanabhan, MD, MA, PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors
Teaching Level: Basic to Intermediate
Objectives:
- Review relevant testing performed on ABO- incompatible HSCT recipients including methodologies, limitations and utilizations.
- Describe appropriate processing methodologies, expected end points and release criteria for cellular products used in ABO- incompatible HSCT.
- Discuss potential consequences and transplant outcomes in the ABO-incompatible HSCT setting.
- Review approaches to safe product infusion, post transplantation monitoring and transfusion policies for ABO-incompatible HSCT recipients.
Event Description: ABO incompatibility is not considered a barrier to successful HSCT. It occurs in 40-50% of all allogeneic HSCTs and requires the careful attention of the recipient's physician as well as the transfusion and cell processing facilities staff. This audioconference will describe current approaches in dealing with ABO-incompatible HSCT in order to lessen potential complications and optimize favorable outcomes. The speakers will discuss patient related issues including testing, transfusion policies, infusion practices, and post transplant monitoring. In addition, cellular product testing, processing methods and criteria for acceptability will be reviewed.
*Cellular Therapy-focused Audioconference.
Register Now
Designing SOPS for Learners
Wednesday, November 14, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124691
Director/Moderator: Jayanna Slayten, MS, MT(ASCP)SBB
Speakers: Keltie Cameron-Choi; Shanta Rohse
Intended Audience: Technologists, Nurses, Managers/Supervisors
Teaching Level: Basic to Intermediate
Objectives:
- Review how we perceive, understand and acquire information according to recent findings published in the cognitive science literature.
- Identify 10 cognitive principles that help us design SOPs that are easier for our staff to understand.
- Demonstrate these principles in action with before and after work instructions.
Event Description: In this presentation, ten cognitive principles derived from cognitive science research will be covered. These principles should be used as guidelines for designing more effective operating procedures. Procedures should be designed to leverage the strengths of how individuals learn and to compensate for our cognitive limitations. Underpinning these guidelines is the principle that vision is the dominant sense we use to absorb information and that our brains are wired for pictures. The use of voluminous written text in a procedure can foster confusion, misinterpretation, and the inability to follow the procedure. The speakers of this audioconference will present several examples of "before and after" procedures that are transformed from incomprehensible to comprehensible and from forgetful to memorable when these principles are applied. The overall intention and focus of this presentation is to inspire new ways of designing SOPs that inform rather than confuse.
Register Now
Kidd Blood Group System Review
Wednesday, November 21, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124721
Director/Moderator: Monica LaSarre, MT(ASCP)SBB
Speaker: Katrina Billingsley, MT(ASCP)
Intended Audience: Physicians, Technologists, Managers/Supervisors
Teaching Level: Basic to Intermediate
Objectives:
- List the antigens included in the Kidd blood group system and include unique characteristics of the antigens in this system.
- Describe antibodies to Kidd blood group system antigens, including serologic characteristics.
- Identify or correlate clinical significance with the antibodies and antigens of the Kidd blood group system.
- Discuss recent findings or case reports associated with the Kidd blood group system.
Event Description: Blood bankers first became aware of the Kidd blood group system in the early 1950s. Since that time, the Kidd system has garnered and retained a reputation amongst transfusion medicine professionals as being especially significant. Its antibodies, though often difficult to detect, are a common cause of hemolytic transfusion reactions. This session will cover a primer of the Kidd blood group system and give a wide range of information about the antigens and antibodies associated with it.
Register Now
Leadership Management Audioconference for Individuals: Should Employee Progressive Discipline, Deviation Management and Accountability be Linked?
Tuesday, December 4, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 1205
Director/Moderator: Shelvi McFadden, MLS(ASCP)
Speaker: Patrick Ooley, MS, MT(ASCP), CQA(ASQ)CMQ/OE
Intended Audience: Technologists, Managers/Supervisors
Teaching Level: Intermediate
Objectives:
- Discuss how deviations or errors relate to employee progressive discipline
- Outline methods to distinguish between steps for improving a process vs. enacting steps for progressive discipline in response to an error.
- Develop a model policy on how errors can be linked to progressive discipline.
- Tie deviation management to individual and organizational accountability.
Event Description: Deviation management is a vital component of organizational quality improvement and compliance. While the discovery and reporting of errors has a primary goal to improve processes, very often management chooses to point the finger at the employee. Should deviation management be linked to employee discipline? Robust deviation management approaches evaluate both processes and staff involved in a deviation. Determining thresholds or steps to distinguish between improvement actions vs. employee actions (discipline) is an ongoing challenge. This workshop will explore methods to link process and error investigations to employee involvement. The speakers will share a process that will provide suggestions on how and when employee progressive discipline may be appropriate. Personal and organizational accountability concepts will also be discussed.
Register Now
Physician Transfusion Medicine Educational Challenges and Triumphs
Wednesday, December 5, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124722
Director/Moderator: Jayanna Slayten, MS, MT(ASCP)SBB
Speakers: Julie Cruz, MD; Gregurek Steve, MD
Intended Audience: Physicians, Technologists, Managers/Supervisors, CEOs/CFOs
Teaching Level: Intermediate to Advanced
Objectives:
- Discuss the challenges for teaching transfusion medicine for physicians.
- Discover effective educational methods for physicians in transfusion medicine.
- Review of the role of the attending, fellow and resident in transfusion medicine education.
Event Description: With the ever growing aspects of transfusion medicine, the education of transfusion medicine physicians continues to be a challenge. This session will explore some of the challenges and triumphs in education today's transfusion medicine experts.
Register Now
1:1:1 Ratio of Massive Transfusion
Wednesday, December 12, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124723
Director/Moderator: Shelvi McFadden, MLS(ASCP)
Speaker: John Holcomb, MD, FACS
Intended Audience: Physicians, Scientists, Technologists, Managers/Supervisors
Teaching Level: Intermediate to Advanced
Objectives:
- Define what determines the need for an MTP to be initiated.
- Assess how much blood should be available for MTP patients.
- Discuss if the use of a 1:1:1 ratio of blood products is appropriate or necessary.
Event Description: Patients suffering from traumatic injuries require aggressive treatment. Massive blood loss may be apparent but the mechanism to stop the bleeding may not. The use of a Massive Transfusion Protocol (MTP) is necessary for these patients in order to stabilize the patient and stop the bleeding. But what is the appropriate ratio of blood products needed for these patients? This program will look at the use of a 1:1:1 ratio of blood products and the benefits of this ratio.
Register Now
CDC's Hemovigilance Module of the National Healthcare Safety Network: How Your Hospital Can Monitor Transfusion-related Adverse Events
FREE SESSION
Wednesday, December 19, 2012
2:00-3:30PM (ET) 7:00-8:30 (GMT)
Program # 124727
Director/Moderator: Barbee Whitaker, PhD
Speaker: Alexis Harvey, MSPH
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors, Perfusionists
Teaching Level: Intermediate
Objectives:
- Demonstrate major features of the Hemovigilance Module of the National Healthcare Safety Network.
- Explain how CDC will protect the hemovigilance data received from facilities.
- Explain how participating facilities can use their own data for process improvements.
- Describe the steps necessary for facilities to join NHSN.
Event Description: CDC representatives will conduct a live demonstration of the National Healthcare Safety Network Hemovigilance Module, a surveillance system available free to US Healthcare facilities to monitor transfusion-related adverse reactions and process incidents. This program will be utilizing webinar software so please make sure you will have internet access during the presentation. One free registration per site is offered for this program.
Register Now
Continuing Education Credit
Access your continuing education credit certificates online!
All audioconference participants will be granted access to their CE credits and attendance verifications online after completing a short evaluation. All credits will be personalized, tracked and maintained online so that participants can access their records at any time. Simply fill in the attendance sheet with the necessary information (including an email address for each participant) and visit the Live Learning Center at www.aabb.org/livelearningcenter at least 48 hours after the audioconference. Only those participants who signed the attendance sheet will be granted the appropriate continuing education credits.
Continuing Medical Education Credit
AABB is accredited by the Accreditation Council on Continuing Medical Education, provider number 0000381, to provide continuing medical education for physicians. AABB designates each audioconference for a maximum of 1.5 contact hours in Category 1 credit toward the American Medical Association Physicians' Recognition Award. Each physician should claim only those credit hours spent in the activity.
California Nurses
AABB is approved by the California Board of Registered Nursing, provider number 4341, as a provider of continuing nursing education activities. AABB designates each audioconference for a maximum of 1.8 contact hours. California nurses must provide a personal signature and other required information on the attendance form.
California Clinical Laboratory Personnel
AABB is an approved accrediting agency for continuing education for California-licensed clinical laboratory personnel. Each audioconference has been approved for a maximum of 1.5 contact hours. AABB's accrediting agency number is 0011. California clinical laboratory personnel must provide a personal signature and other required information on the attendance form. Credit earned through attendance at audioconferences may be used to fulfill the state requirement for continuing education hours to maintain licensure status.
Florida Clinical Laboratory Personnel
AABB is approved by the Florida Board of Clinical Laboratory Personnel, Provider Number 50-4261-1, as a provider of continuing education programs for Florida-licensed clinical laboratory personnel. Each audioconference has been approved for a maximum of 1.8 contact hours. Florida clinical laboratory personnel must provide a personal signature and other required information on the attendance form.
Ireland
The Professional Enhancement Program (PEP) of the Irish Academy of Medical Laboratory Sciences will offer credit for AABB audioconferences. PEP registrants who participate within the Blood Transfusion Service Board will receive PEP certificates of attendance at no additional charge.
United Kingdom
The Institute of Biomedical Science (IBMS) in the United Kingdom accredits AABB for Continuing Professional Development. Those who have registered on the IBMS Scheme will earn 0.2 educational category credit towards the annual 4.0 credit requirement. Participants are asked to use reference # TS011N98. Questions regarding continuing education credits should be directed to the AABB Professional Development Department at +1.301.215.6482 or professionaldevelopment@aabb.org.